Hansen E, Zech N, Benson S
Klinik für Anästhesiologie, Universitätsklinikum Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Deutschland.
Institut für Medizinische Psychologie und Verhaltensbiologie, Universitätsklinikum Essen, Essen, 45122, Deutschland.
Nervenarzt. 2020 Aug;91(8):691-699. doi: 10.1007/s00115-020-00963-4.
Negative previous experiences (conditioning), observational learning and expectations can trigger nocebo effects. They are responsible for a substantial proportion of the side effects of medical treatment, and are induced primarily by risk information for informed consent. This has been demonstrated in studies on patient groups with or without modified medical information. Drug trials in the field of neurology and psychiatry have regularly revealed side effects and drop-out also in placebo groups. The underlying neurobiological mechanisms were experimentally investigated especially for nocebo-induced hyperalgesia, whereby the specifically involved regions of the brain could be identified by functional imaging as well as changes in the dopamine, endorphin and cholecystokinin systems. Nocebo effects are specific, i.e. they are closely related to patient information and can induce or aggravate exactly the symptoms addressed. Nevertheless, informed consent is an essential part of doctor-patient communication; however, information on risks can be markedly less damaging when unnecessary repetitions are avoided, misunderstandings are recognized or resolved and several different options are given. In addition, risks should always be named together with positive aspects, such as the advantages of the appropriate treatment, the prophylactic measures applied or the early detection and treatment of developing side effects. The best protection against harm caused by information on risks is a trustful doctor-patient relationship. Poor knowledge of nocebo effects or lack of countermeasures constitute a serious threat to patients and according to the current state of knowledge could be rated as medical malpractice.
既往的负面经历(条件作用)、观察性学习和期望可引发反安慰剂效应。它们在很大程度上导致了药物治疗的副作用,主要由知情同意过程中的风险信息所诱发。这一点在针对有或没有修改过的医疗信息的患者群体的研究中得到了证实。神经病学和精神病学领域的药物试验经常表明,安慰剂组也会出现副作用和受试者退出试验的情况。尤其是针对反安慰剂诱导的痛觉过敏,对其潜在的神经生物学机制进行了实验研究,通过功能成像以及多巴胺、内啡肽和胆囊收缩素系统的变化,可以确定大脑中具体涉及的区域。反安慰剂效应具有特异性,也就是说,它们与患者所获得的信息密切相关,能够诱发或加重所提及的症状。然而,知情同意是医患沟通的重要组成部分;不过,如果避免不必要的重复、识别或解决误解并提供几种不同的选择,关于风险的信息造成的损害可能会明显减少。此外,在提及风险的同时,应该始终提及积极方面,例如适当治疗的益处、所采取的预防措施或对正在出现的副作用的早期发现和治疗。防范风险信息造成伤害的最佳保护措施是医患之间的信任关系。对反安慰剂效应了解不足或缺乏应对措施对患者构成严重威胁,根据目前的知识水平,这可被视为医疗过失。